Dissociation of the α2-adrenergic antinociception from sedation following microinjection of medetomidine into the locus coeruleus in rats

It is well established that α-adrenoceptor agonists have sedative and antinociceptive properties. In the current behavioral study we tried to find out if the α-adrenergic sedative and antinociceptive effects can be dissociated. We tested the hypothesis that α adrenergic sedation is mediated by the l...

Full description

Saved in:
Bibliographic Details
Published inPain (Amsterdam) Vol. 57; no. 2; pp. 207 - 215
Main Authors Pertovaara, Antti, Hämäläinen, Minna M., Kauppila, Timo, Mecke, Ernst, Carlson, Synnöve
Format Journal Article
LanguageEnglish
Published Amsterdam Elsevier B.V 1994
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:It is well established that α-adrenoceptor agonists have sedative and antinociceptive properties. In the current behavioral study we tried to find out if the α-adrenergic sedative and antinociceptive effects can be dissociated. We tested the hypothesis that α adrenergic sedation is mediated by the locus coeruleus (LC) and antinociception by spinal α-adrenoceptors. Also, we addressed the possibility that intracerebral injection of an α-agonist might produce its antinociceptive effect by an action directly at the spinal cord. Medetomidine, an α-adrenergic agonist, or atipamezole, an α-adrenergic antagonist, were microinjected bilaterally into the LC through chronic cannulae in unanesthetized Han-Wistar rats. The effect on locomotor activity (/vigilancc). tail-flick and hot-plate response, and on formalin-induced pain behavior was determined. Medetomidine microinjected into the LC (1–10 μg/cannula) produced dose-dependently hypolocomotion (/sedation), increase of response latencies in the hot-plate and the tail-flick tests, and a decrease in the formalin-induced pain behavior. Hypolocomotion (/sedation) was obtained at a lower medetomidine dose (1 μg/cannula) than antinociception (3–10 μg/cannula). The lowest medetomidine dose used (1 μg/cannula), which induced significant hypolocomotion (/sedation), produced either no antinociception (hot-plate and tail-flick tests) or even a slight hyperalgesia (formalin test). The hypolocomotion (/sedation) but not antinociception (tail-flick test) induced by systemic administration of medetomidine (100 μg/kg s.c.) could be reversed by atipamezole (10 μg/cannula) microinjected into the LC. Only a high systemic dose of atipamezole (1 mg/kg s.c.) reversed the antinociceptive effects of medetomidine. Microinjection of medetomidine into the LC (3 μg/cannula) produced antinociception (tail-flick test) also in spinal rats. which effect was completely reversed by atipamezole (l mg/kg s.c.). Following administration of medetomidine at the dose of 1 μg/cannula into the central or cortical nucleus of the amygdala (control sites) there was no significant effect on locomotor activity, hot-plate response, or formalin-induced pain. The results indicate that α-adrenergic sedative and pain-modulating effects can be dissociated following microinjection of medetomidine into the LC. The antinociceptive effect of the supraspinally microinjected medetomidine in Han-Wistar rats could be explained by direct activation of the spinal α-adrenoceptors, whereas the sedation/hypolocomotion could he explained by an action on the α-adrenoceptors located in the LC, or its immediate vicinity.
ISSN:0304-3959
1872-6623
DOI:10.1016/0304-3959(94)90225-9